A Synthetic Virus-Like Particle Streptococcal Vaccine Candidate Using B-Cell Epitopes from the Proline-Rich Region of Pneumococcal Surface Protein A
Alternatives to the well-established capsular polysaccharide-based vaccines against Streptococcus pneumoniae that circumvent limitations arising from limited serotype coverage and the emergence of resistance due to capsule switching (serotype replacement) are being widely pursued. Much attention is...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2015-10-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2076-393X/3/4/850 |
| _version_ | 1828120154193526784 |
|---|---|
| author | Marco Tamborrini Nina Geib Aniebrys Marrero-Nodarse Maja Jud Julia Hauser Celestine Aho Araceli Lamelas Armando Zuniga Gerd Pluschke Arin Ghasparian John A. Robinson |
| author_facet | Marco Tamborrini Nina Geib Aniebrys Marrero-Nodarse Maja Jud Julia Hauser Celestine Aho Araceli Lamelas Armando Zuniga Gerd Pluschke Arin Ghasparian John A. Robinson |
| author_sort | Marco Tamborrini |
| collection | DOAJ |
| description | Alternatives to the well-established capsular polysaccharide-based vaccines against Streptococcus pneumoniae that circumvent limitations arising from limited serotype coverage and the emergence of resistance due to capsule switching (serotype replacement) are being widely pursued. Much attention is now focused on the development of recombinant subunit vaccines based on highly conserved pneumococcal surface proteins and virulence factors. A further step might involve focusing the host humoral immune response onto protective protein epitopes using as immunogens structurally optimized epitope mimetics. One approach to deliver such epitope mimetics to the immune system is through the use of synthetic virus-like particles (SVLPs). SVLPs are made from synthetic coiled-coil lipopeptides that are designed to spontaneously self-assemble into 20–30 nm diameter nanoparticles in aqueous buffer. Multivalent display of epitope mimetics on the surface of SVLPs generates highly immunogenic nanoparticles that elicit strong epitope-specific humoral immune responses without the need for external adjuvants. Here, we set out to demonstrate that this approach can yield vaccine candidates able to elicit a protective immune response, using epitopes derived from the proline-rich region of pneumococcal surface protein A (PspA). These streptococcal SVLP-based vaccine candidates are shown to elicit strong humoral immune responses in mice. Following active immunization and challenge with lethal doses of streptococcus, SVLP-based immunogens are able to elicit significant protection in mice. Furthermore, a mimetic-specific monoclonal antibody is shown to mediate partial protection upon passive immunization. The results show that SVLPs combined with synthetic epitope mimetics may have potential for the development of an effective vaccine against Streptococcus pneumoniae. |
| first_indexed | 2024-04-11T13:59:38Z |
| format | Article |
| id | doaj.art-bd3ac40b3b114e489cb401e7e801ed34 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-04-11T13:59:38Z |
| publishDate | 2015-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-bd3ac40b3b114e489cb401e7e801ed342022-12-22T04:20:09ZengMDPI AGVaccines2076-393X2015-10-013485087410.3390/vaccines3040850vaccines3040850A Synthetic Virus-Like Particle Streptococcal Vaccine Candidate Using B-Cell Epitopes from the Proline-Rich Region of Pneumococcal Surface Protein AMarco Tamborrini0Nina Geib1Aniebrys Marrero-Nodarse2Maja Jud3Julia Hauser4Celestine Aho5Araceli Lamelas6Armando Zuniga7Gerd Pluschke8Arin Ghasparian9John A. Robinson10Swiss Tropical and Public Health Institute, Socinstrasse 57, Basel 4051, SwitzerlandVirometix AG, Wagistrasse 14, Schlieren 8952, SwitzerlandVirometix AG, Wagistrasse 14, Schlieren 8952, SwitzerlandSwiss Tropical and Public Health Institute, Socinstrasse 57, Basel 4051, SwitzerlandSwiss Tropical and Public Health Institute, Socinstrasse 57, Basel 4051, SwitzerlandSwiss Tropical and Public Health Institute, Socinstrasse 57, Basel 4051, SwitzerlandSwiss Tropical and Public Health Institute, Socinstrasse 57, Basel 4051, SwitzerlandVirometix AG, Wagistrasse 14, Schlieren 8952, SwitzerlandSwiss Tropical and Public Health Institute, Socinstrasse 57, Basel 4051, SwitzerlandVirometix AG, Wagistrasse 14, Schlieren 8952, SwitzerlandDepartment of Chemistry, University of Zürich, Winterthurerstrasse 190, Zürich 8057, SwitzerlandAlternatives to the well-established capsular polysaccharide-based vaccines against Streptococcus pneumoniae that circumvent limitations arising from limited serotype coverage and the emergence of resistance due to capsule switching (serotype replacement) are being widely pursued. Much attention is now focused on the development of recombinant subunit vaccines based on highly conserved pneumococcal surface proteins and virulence factors. A further step might involve focusing the host humoral immune response onto protective protein epitopes using as immunogens structurally optimized epitope mimetics. One approach to deliver such epitope mimetics to the immune system is through the use of synthetic virus-like particles (SVLPs). SVLPs are made from synthetic coiled-coil lipopeptides that are designed to spontaneously self-assemble into 20–30 nm diameter nanoparticles in aqueous buffer. Multivalent display of epitope mimetics on the surface of SVLPs generates highly immunogenic nanoparticles that elicit strong epitope-specific humoral immune responses without the need for external adjuvants. Here, we set out to demonstrate that this approach can yield vaccine candidates able to elicit a protective immune response, using epitopes derived from the proline-rich region of pneumococcal surface protein A (PspA). These streptococcal SVLP-based vaccine candidates are shown to elicit strong humoral immune responses in mice. Following active immunization and challenge with lethal doses of streptococcus, SVLP-based immunogens are able to elicit significant protection in mice. Furthermore, a mimetic-specific monoclonal antibody is shown to mediate partial protection upon passive immunization. The results show that SVLPs combined with synthetic epitope mimetics may have potential for the development of an effective vaccine against Streptococcus pneumoniae.http://www.mdpi.com/2076-393X/3/4/850peptidestreptococcussynthetic virus-like particlePspAvaccine |
| spellingShingle | Marco Tamborrini Nina Geib Aniebrys Marrero-Nodarse Maja Jud Julia Hauser Celestine Aho Araceli Lamelas Armando Zuniga Gerd Pluschke Arin Ghasparian John A. Robinson A Synthetic Virus-Like Particle Streptococcal Vaccine Candidate Using B-Cell Epitopes from the Proline-Rich Region of Pneumococcal Surface Protein A Vaccines peptide streptococcus synthetic virus-like particle PspA vaccine |
| title | A Synthetic Virus-Like Particle Streptococcal Vaccine Candidate Using B-Cell Epitopes from the Proline-Rich Region of Pneumococcal Surface Protein A |
| title_full | A Synthetic Virus-Like Particle Streptococcal Vaccine Candidate Using B-Cell Epitopes from the Proline-Rich Region of Pneumococcal Surface Protein A |
| title_fullStr | A Synthetic Virus-Like Particle Streptococcal Vaccine Candidate Using B-Cell Epitopes from the Proline-Rich Region of Pneumococcal Surface Protein A |
| title_full_unstemmed | A Synthetic Virus-Like Particle Streptococcal Vaccine Candidate Using B-Cell Epitopes from the Proline-Rich Region of Pneumococcal Surface Protein A |
| title_short | A Synthetic Virus-Like Particle Streptococcal Vaccine Candidate Using B-Cell Epitopes from the Proline-Rich Region of Pneumococcal Surface Protein A |
| title_sort | synthetic virus like particle streptococcal vaccine candidate using b cell epitopes from the proline rich region of pneumococcal surface protein a |
| topic | peptide streptococcus synthetic virus-like particle PspA vaccine |
| url | http://www.mdpi.com/2076-393X/3/4/850 |
| work_keys_str_mv | AT marcotamborrini asyntheticviruslikeparticlestreptococcalvaccinecandidateusingbcellepitopesfromtheprolinerichregionofpneumococcalsurfaceproteina AT ninageib asyntheticviruslikeparticlestreptococcalvaccinecandidateusingbcellepitopesfromtheprolinerichregionofpneumococcalsurfaceproteina AT aniebrysmarreronodarse asyntheticviruslikeparticlestreptococcalvaccinecandidateusingbcellepitopesfromtheprolinerichregionofpneumococcalsurfaceproteina AT majajud asyntheticviruslikeparticlestreptococcalvaccinecandidateusingbcellepitopesfromtheprolinerichregionofpneumococcalsurfaceproteina AT juliahauser asyntheticviruslikeparticlestreptococcalvaccinecandidateusingbcellepitopesfromtheprolinerichregionofpneumococcalsurfaceproteina AT celestineaho asyntheticviruslikeparticlestreptococcalvaccinecandidateusingbcellepitopesfromtheprolinerichregionofpneumococcalsurfaceproteina AT aracelilamelas asyntheticviruslikeparticlestreptococcalvaccinecandidateusingbcellepitopesfromtheprolinerichregionofpneumococcalsurfaceproteina AT armandozuniga asyntheticviruslikeparticlestreptococcalvaccinecandidateusingbcellepitopesfromtheprolinerichregionofpneumococcalsurfaceproteina AT gerdpluschke asyntheticviruslikeparticlestreptococcalvaccinecandidateusingbcellepitopesfromtheprolinerichregionofpneumococcalsurfaceproteina AT aringhasparian asyntheticviruslikeparticlestreptococcalvaccinecandidateusingbcellepitopesfromtheprolinerichregionofpneumococcalsurfaceproteina AT johnarobinson asyntheticviruslikeparticlestreptococcalvaccinecandidateusingbcellepitopesfromtheprolinerichregionofpneumococcalsurfaceproteina AT marcotamborrini syntheticviruslikeparticlestreptococcalvaccinecandidateusingbcellepitopesfromtheprolinerichregionofpneumococcalsurfaceproteina AT ninageib syntheticviruslikeparticlestreptococcalvaccinecandidateusingbcellepitopesfromtheprolinerichregionofpneumococcalsurfaceproteina AT aniebrysmarreronodarse syntheticviruslikeparticlestreptococcalvaccinecandidateusingbcellepitopesfromtheprolinerichregionofpneumococcalsurfaceproteina AT majajud syntheticviruslikeparticlestreptococcalvaccinecandidateusingbcellepitopesfromtheprolinerichregionofpneumococcalsurfaceproteina AT juliahauser syntheticviruslikeparticlestreptococcalvaccinecandidateusingbcellepitopesfromtheprolinerichregionofpneumococcalsurfaceproteina AT celestineaho syntheticviruslikeparticlestreptococcalvaccinecandidateusingbcellepitopesfromtheprolinerichregionofpneumococcalsurfaceproteina AT aracelilamelas syntheticviruslikeparticlestreptococcalvaccinecandidateusingbcellepitopesfromtheprolinerichregionofpneumococcalsurfaceproteina AT armandozuniga syntheticviruslikeparticlestreptococcalvaccinecandidateusingbcellepitopesfromtheprolinerichregionofpneumococcalsurfaceproteina AT gerdpluschke syntheticviruslikeparticlestreptococcalvaccinecandidateusingbcellepitopesfromtheprolinerichregionofpneumococcalsurfaceproteina AT aringhasparian syntheticviruslikeparticlestreptococcalvaccinecandidateusingbcellepitopesfromtheprolinerichregionofpneumococcalsurfaceproteina AT johnarobinson syntheticviruslikeparticlestreptococcalvaccinecandidateusingbcellepitopesfromtheprolinerichregionofpneumococcalsurfaceproteina |